Phase II Open Label Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus Pulmonary Disease
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Safety and tolerability
研究概览
简要总结
- To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M. abscessus-pulmonary disease
- To assess the safety and tolerability of RESP301 during treatment (28 days) and follow up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment refractory M. abscessus-pulmonary disease
详细描述
Investigators will undertake an eighteen-week single centre, open label study in participants with cystic fibrosis infected with Mycobacterium abscessus (M. abscessus)-pulmonary disease (-PD).
The study will treat particpants with cystic fibrosis (CF) attending the Adult Cystic Fibrosis Centre at the Royal Papworth Hospital, Cambridge, United Kingdom. Participants will be consented and screened for the RESP301-003 study to enable approximately 12 participants to commence treatment with RESP301.
Participants will have M abscessus-PD as defined by the ATS/IDSA, specifically: (i) two or more positive sputum cultures for M. abscessus; (ii) radiological change consistent with NTM-PD; and (iii) symptoms consistent with NTM-PD, after exclusion of other causes.
Participants will be recruited who (1) have not commenced antibiotic treatment for M. abscessus-PD or (2) have treatment refractory M. abscessus-PD (defined as remaining sputum culture positive after 6 months or more of treatment). Treatment-refractory participants will be suitable for enrolment in the study if date of first dosing is at least 2 months since a change in M. abscessus treatment (or 4 months since change of Clofazimine).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients of ≥18 years at time of informed consent
- •Patients with a clinical diagnosis of CF and confirmed by genetic testing
- •Diagnosis of treatment naïve or treatment refractory M. abscessus-PD
- •Signed informed consent documentation (indicating an understanding of the purpose and a willingness to meet the requirements for participation in the study)
排除标准
- •FEV1 <40% predicted
- •Methaemoglobin concentration > 2%
- •Use of nitric oxide donor medications such as prilocaine, sodium nitroprusside, and nitroglycerine within 30 days of proposed first treatment
- •Use of phosphodiesterase inhibitors (e.g., sildenafil) within 30 days of proposed first treatment
- •Evidence of pulmonary hypertension
- •History of frequent low volume or massive haemoptysis
- •Liver disease (i.e. liver cirrhosis, portal hypertension)
- •Subjects who have undergone organ transplantation
- •Pregnancy or lactation (female participants only)
- •Subjects who will not use appropriate forms of contraception for the duration of the study
- •Contraindication or unable to complete lung function testing
- •Contraindication or unable to tolerate nebulised hypertonic saline
- •Changes to previous NTM antibiotic regimen within two months of first dose of study treatment (or 4 months for clofazimine)
- •Subject has received investigational treatment as part of another interventional clinical trial within two months of the proposed first day of treatment
- •Required antibiotic treatment for a pulmonary exacerbation within 2 weeks of enrolment to the study.
- •Inability to undergo study related activities and / or commitments
- •Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial.
研究组 & 干预措施
Interventional
Single arm trial involving all patients receiving IMP
干预措施: RESP301 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: Through study completion, average one year
Safety and tolerability will be assessed by clinical safety laboratory measurements, physical examinations, vital signs, concomitant medications; cumulative incidence of adverse events (AEs), serious adverse events (SAEs) and severe AEs.
Mycobacterial load in induced sputum samples
时间窗: Through study completion, average one year
The primary efficacy endpoint is the change in mycobacterial load in induced sputum samples as assessed by log10 change in M. abscessus cfu/g sputum from Baseline to End of Treatment.
次要结局
- Proportion of individuals achieving a ≥2 log10 decrease in the mycobacterial load - induced samples(Through study completion, average one year)
- Change in mycobacterial load in spontaneously expectorated daily sputum samples(Through study completion, average one year)
- Proportion of individuals achieving a ≥2 log10 decrease in the mycobacterial load - spontaneous samples(Through study completion, average one year)